IQVIA (NYSE:IQV) PT Lowered to $230.00 at Evercore ISI

IQVIA (NYSE:IQV) had its target price trimmed by Evercore ISI from $250.00 to $230.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the medical research company’s stock.

A number of other analysts have also weighed in on IQV. Barclays lowered their target price on IQVIA from $275.00 to $255.00 and set an overweight rating for the company in a report on Friday, June 28th. Robert W. Baird lowered their target price on IQVIA from $254.00 to $245.00 and set a neutral rating for the company in a report on Friday, May 3rd. Truist Financial lowered their target price on IQVIA from $297.00 to $292.00 and set a buy rating for the company in a report on Friday, May 3rd. StockNews.com lowered IQVIA from a buy rating to a hold rating in a report on Sunday, July 7th. Finally, The Goldman Sachs Group assumed coverage on IQVIA in a report on Thursday, June 6th. They set a buy rating and a $270.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $255.73.

IQVIA Stock Up 3.5 %

Shares of NYSE:IQV opened at $219.44 on Tuesday. IQVIA has a 52-week low of $167.42 and a 52-week high of $261.73. The stock has a market cap of $39.98 billion, a P/E ratio of 29.98, a price-to-earnings-growth ratio of 1.93 and a beta of 1.49. The business’s 50 day moving average is $219.70 and its 200 day moving average is $229.03. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The company had revenue of $3.74 billion for the quarter, compared to analysts’ expectations of $3.69 billion. Sell-side analysts predict that IQVIA will post 10.11 EPS for the current year.

Hedge Funds Weigh In On IQVIA

Several hedge funds have recently made changes to their positions in IQV. Los Angeles Capital Management LLC grew its position in IQVIA by 17.5% during the 4th quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock worth $27,445,000 after purchasing an additional 17,677 shares during the period. Jennison Associates LLC grew its position in IQVIA by 7.3% during the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock worth $35,636,000 after purchasing an additional 9,578 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in IQVIA by 4.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after purchasing an additional 93,194 shares during the period. Cadian Capital Management LP acquired a new stake in IQVIA during the 4th quarter worth about $70,108,000. Finally, Nomura Holdings Inc. acquired a new stake in IQVIA during the 4th quarter worth about $857,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.